Author

E. Stefanidis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:genetic perturbation / CRISPR· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

B. Seijo· 2 shared G. Coukos· 2 shared M. Irving· 2 shared A. Semilietof· 1 shared A. Spill· 1 shared C. Jimenez-Luna· 1 shared C. Ronet· 1 shared E. Lanitis· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

B. Seijo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combination of NY-ESO-1-TCR-T-cells coengineered to secrete SiRPalpha decoys with anti-tumor antibodies to augment macrophage phagocytosis

E. Stefanidis, A. Semilietof, J. Pujol, B. Seijo, K. Scholten, V. Zoete, O. Michielin, R. Sandaltzopoulos, G. Coukos, M. Irving

This study combines NY-ESO-1 TCR-T cells secreting SiRPalpha decoys with anti-tumor antibodies to enhance macrophage phagocytosis and improve tumor control.

bioRxiv · Jun 27, 2023Bioengineering

Orthogonal Gene Engineering Enables CD8+ T Cells to Control Tumors through a Novel PD-1+ TOX-indifferent Synthetic Effector State

J. Corria-Osorio, S. J. Carmona, E. Stefanidis, M. J. Andreatta, T. Muller, Y. Ortiz, B. Seijo, W. Castro, C. Jimenez-Luna, L. Scarpellino, C. Ronet, A. Spill, E. Lanitis, S. A. Luther, P. Romero, , G. Coukos

This study shows that orthogonal gene engineering of CD8+ T cells with IL-2 variant, PD1-decoy, and IL-33 enables tumor control through a novel PD-1+ TOX-indifferent synthetic effector state.

bioRxiv · Feb 18, 2022 · PreprintImmunology